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ABSTRACT
Hypoxia-ischemia (HI) can result in permanent life-long injuries such as motor 
and cognitive deficits. In response to cellular stressors such as hypoxia, tumor 
suppressor protein p53 is activated, potently initiating apoptosis and promoting 
Bax-dependent mitochondrial outer membrane permeabilization. The aim of this 
study was to investigate the effect of Trp53 genetic inhibition on injury development 
in the immature brain following HI. HI (50 min or 60 min) was induced at postnatal 
day 9 (PND9) in Trp53 heterozygote (het) and wild type (WT) mice. Utilizing Cre-
LoxP technology, CaMK2α-Cre mice were bred with Trp53-Lox mice, resulting in 
knockdown of Trp53 in CaMK2α neurons. HI was induced at PND12 (50 min) and 
PND28 (40 min). Extent of brain injury was assessed 7 days following HI. Following 
50 min HI at PND9, Trp53 het mice showed protection in the posterior hippocampus 
and thalamus. No difference was seen between WT or Trp53 het mice following a 
severe, 60 min HI. Cre-Lox mice that were subjected to HI at PND12 showed no 
difference in injury, however we determined that neuronal specific CaMK2α-Cre 
recombinase activity was strongly expressed by PND28. Concomitantly, Trp53 was 
reduced at 6 weeks of age in KO-Lox Trp53 mice. Cre-Lox mice subjected to HI at 
PND28 showed no significant difference in brain injury. These data suggest that p53 
has a limited contribution to the development of injury in the immature/juvenile 
brain following HI. Further studies are required to determine the effect of p53 on 
downstream targets.
INTRODUCTION
Hypoxic-ischemic encephalopathy (HIE), caused 
by a lack of oxygen or blood flow to the brain around 
the time of birth, affects 1-2 in every 1000 live births 
in the UK [1] and far more in the developing world [2]. 
The consequences for babies and parents affected by 
HIE are devastating with a high proportion of survivors 
suffering from severe and long-lasting motor and 
cognitive impairments [3]. Neuroprotective therapy 
with hypothermia improves outcome and prevents death 
or neurological outcome in one in seven babies which 
represents a breakthrough in the care of these vulnerable 
neonates [4]. Although therapeutic hypothermia is not 
universally successful, it provides proof-of-concept 
that intervention following injury can offer significant 
benefit. However, in order to provide additional more 
effective therapies we urgently require a more thorough 
understanding of the underlying pathophysiology.
Brain injury develops in different phases following 
hypoxia-ischemia (HI) depending on the brain region 
and severity of the primary insult [5, 6]. Cell death after 
neonatal brain injury is characterized morphologically by 
a mixed necrotic, necroptotic, autophagic and apoptotic 
phenotype [7-10], with predominantly neurons vulnerable 
to insult in the near term brain. However, data from our 
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lab and others strongly suggest that the common thread 
linking these diverse mechanisms is mitochondrial 
perturbation [11-13].
HI triggers multiple signaling events such as 
excitotoxicity, release of reactive oxygen species and 
increase in intracellular calcium [5, 6, 11, 12]. Bcl-
2 family member Bax is activated and translocates to 
the mitochondria where it and family member Bak 
homo-oligomerise forming pores ultimately leading to 
mitochondrial outer membrane permeabilization (MOMP) 
[5]. MOMP allows the efflux of pro-apoptotic proteins 
such as cytochrome c and apoptosis inducing factor 
(AIF) into the cytosol [13-17] thereby initiating a cascade 
resulting in activation of caspases, degradation of DNA 
and ultimately cell death [14, 15, 18].
It is, however, still unclear how MOMP is initiated. 
Besides changes in pro- vs. anti-apoptotic Bcl-2 protein 
ratio, several other upstream regulators may be involved 
such as caspase-2 and c-Jun N-terminal kinase (JNK) 
[19, 20]. The tumor suppressor protein p53 (Trp53 
mouse gene) is one such candidate recently implicated in 
mediating neuronal cell death observed after neonatal HI. 
Nuclear p53 triggers apoptosis via multiple pathways, for 
example cell cycle arrest, the regulation of autophagy [21], 
through transactivating pro-apoptotic and repressing anti-
apoptotic genes [22]. In addition, p53 also has cytoplasmic 
actions at the mitochondrial level and can promote Bax-
dependent MOMP [23, 24]. Nuclear export of p53 depends 
on mono-ubiquitination by the E3 ubiquitin-ligase Mdm2 
and once at the mitochondria, p53 is deubiquitinated 
by the ubiquitin specific peptidase 7 (HAUSP) [25]. 
Cytosolic p53 is probably inactivated through binding to 
Bcl-XL and/or Mcl-1 [24, 26]. P53 is, however, liberated 
from Bcl-XL/Mcl-1 by high levels of p53 up-regulated 
modulator of apoptosis (PUMA) and can subsequently 
interact with Bax at the outer mitochondrial membrane.
There are several reasons to suspect that p53 is 
important in the context of Bax-dependent MOMP and 
cell death in the neonatal brain. Firstly, the expression 
of p53 and several of its downstream genes are induced 
in the brain after neonatal HI [27, 28]. Secondly, p53, 
PUMA and Noxa accumulate in the cytosol and p53 
translocates to mitochondria after neonatal HI [28-30]. 
Thirdly, inhibiting NFκB (a regulator of p53) by blocking 
IκB-kinase with a Nemo binding domain TAT peptide 
reduces p53 levels and subsequently cytochrome c release 
and brain injury in a neonatal HI mouse model [29-31]. 
Finally, Pifithrin-μ (PFT-μ, inhibitor of the mitochondrial 
actions of p53) [32] blocks mitochondrial accumulation 
of p53, cytochrome c release and subsequent activation 
of caspase-3, substantially reducing neonatal brain injury 
[31]. However, PFT-μ also has effects on microglial 
activation [33] and heat shock proteins (HSP) [34] and we 
still lack convincing genetic proof that p53 is involved.
The aim of the present study is to apply a two-
pronged approach to evaluate whether, firstly, a partial 
gene deficiency of Trp53, comparing Trp53 heterozygote 
mice with wild types, confer neuroprotection in a neonatal 
model of term HI and, secondly, conditional neuronal 
deletion of Trp53 (utilizing CaMK2αCre – Lox Trp53 
mice [35]) affects the extent of HI brain injury in neonatal 
and juvenile mice.
RESULTS
Trp53 hets are less injured at posterior levels of 
the brain following moderate (50 min) but not 
severe (60 min) of hypoxia-ischemia at postnatal 
day (PND) 9
At PND 9, mixed genotype litters of both sexes 
were randomly subjected to either a moderate 50 min or 
severe 60 min episode of HI. Loss of grey matter (MAP-2 
staining) and white matter (MBP staining) was evaluated 
7 days following HI.
Following moderate (50 min) HI, no differences 
in body weight were observed between genotypes at 
PND 9 and PND 16. Analysis of the infarct revealed that 
Trp53 hets (n=18; females n=8, males n=10) showed 
significantly less MAP-2 tissue loss in the posterior levels 
of the brain (Figure 1A, E) compared with Trp53 WT 
(n=21; females n=8, males n=13; 16.1 ± 3.5% vs 30.6 
± 4.0%, p<0.05). No differences were observed at the 
central or anterior levels of the brain. No differences were 
observed in volume tissue loss (Figure 1B) or loss of MBP 
staining (Figure 1C).
The atrophy and infarction (0 to 6) for each region 
of interest (cortex, hippocampus, striatum and thalamus) 
were assessed to obtain a neuropathology score of the left, 
injured, hemisphere (Figure 1D) [36]. Trp53 hets showed 
significantly less injury particularly in the posterior region 
of the hippocampus and the thalamus. A trend towards 
less injury was also seen in the cortex (p=0.058). No 
differences were observed in the striatum. In spite of 
the quite marked protection in the Trp53 het mice in the 
posterior part of the brain, we observed no difference in 
overall volume tissue loss as the central and anterior part 
of the brain including striatum and most parts of cerebral 
cortex were unaffected by p53 genotype.
Following a severe (60 min) duration of HI there 
were no differences between Trp53 WT (n=20; females 
n=11, males n=9) and Trp53 hets (n=29; females n=15, 
males n=14) when assessed at PND 16 for MAP-2 tissue 
loss (Figure 2A), volume tissue loss (Figure 2B) or MBP 
loss (Figure 2C).
No effect of conditional knock-down of Trp53 on 
injury at PND 12
In order to reduce any influence on phenotype due 
to the global absence of p53, we generated a conditional 
Trp53 knockout mouse in which deletion of Trp53 was 
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Figure 1: Brain injury assessment of Trp53 WT (+/+) and Het (+/-) mice 7 days following 50 min HI at PND 9. MAP-2 
tissue loss A. volume tissue loss B. MBP loss C. and neuropathology scores D. were assessed at 8 levels of the brain in Trp53 WT (black 
bars; n=21) and Trp53 het (grey bars; n=16). MAP-2 stained images at posterior levels of the brain from Trp53 WT +/+ E(i). and Trp53 
het +/- E(ii). Mean ± SEM. * p< 0.05, ** p < 0.01, **** p<0.0001. Cortex (Cx), Hippocampus (Hipp), posterior hippocampus (P. Hipp), 
Striatum (Stri), Thalamus (Thal). Scale bar represents 2 mm.
Figure 2: Brain injury assessment of Trp53 WT (+/+) and Het (+/-) mice 7 days following 60 min HI at P9. MAP-2 tissue 
loss A. volume tissue loss B. and MBP loss C. were assessed at 8 levels of the brain in Trp53 WT (black bars; n=20) and Trp53 het (grey 
bars; n=29). Mean ± SEM.
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limited to neurons in the forebrain. We chose to combine 
Trp53-lox animals with mice expressing Cre recombinase 
under the control of the calcium/calmodulin-dependent 
protein kinase II alpha (CaMK2α) promoter. The CaMK2α 
promoter is reported to facilitate early, neuronal expression 
of the gene of interest [37]. PND12 mixed litters consisting 
of WT Lox Trp53+/+ (n=16; females n=7, males n=9) 
and KO Lox Trp53f/+ (n=24; males n=13, females n=11) 
were subjected to 50 min of HI. There was, however, no 
difference between genotypes in MAP-2 tissue loss overall 
or in the hippocampus (data not shown).
CaMK2α Cre activation is initially detected at 
PND 19
In order to investigate the regional and age-
dependent expression of Cre recombinase activity which 
may have influenced the previous result, CaMK2α-Cre 
mice were bred with Rosa26 LacZ reporter mice. X-gal 
staining of β-galactosidase revealed no positive Cre 
recombinase activity (shown by blue stained cells) at 
PND 7 or PND 14. At PND 19, blue stained cells were 
present in the CA1 and CA2 regions of the hippocampus, 
with subtle staining seen in the cortex. By PND 28 strong 
staining was present throughout the hippocampus and 
cortex, at the level of approximately Bregma -2.12mm. 
This was consistent in pups generated from paternal (bred 
with a ROSA26 female) or maternal (bred with a ROSA26 
male) Cre inheritance (Figure 3).
Trp53 messenger RNA expression in CaMK2α 
Cre-Trp53 Lox mice
As antibodies directed towards mouse p53 are 
unreliable for immunohistochemistry (data not shown), to 
confirm CaMK2α Cre-mediated deletion of Trp53 from 
neurons, in situ hybridization was conducted for Trp53 
mRNA in WT Lox Trp53+/+ and KO Lox Trp53f/+ (Figure 4). 
Brains were assessed at PND 7, PND 12 and at 6 weeks of 
age. Trp53 mRNA expression was present at PND 7 and 
PND 12 in both genotypes (Figure 4A, 4B, 4E, 4F). At 6 
weeks of age WT Lox Trp53+/+ (Figure 4C, 4D) exhibited 
Trp53 mRNA staining in the hippocampus, in contrast to 
KO Lox Trp53f/+ that showed sparse hippocampal Trp53 
expression (Figure 4G, 4H). This staining was consistent 
with the regions where we observed Cre-recombinase 
activation, shown by x-gal staining (Figure 3D). 
Traditional Trp53 KO mice served as a negative control 
and no Trp53 mRNA staining was observed throughout 
the brain (Figure 4I, 4J).
Conditional knock-down of Trp53 was not 
protective against hypoxic-ischemic injury at 
PND 28
Based on the LacZ reporter staining and the in situ 
data showing that Trp53 expression was significantly 
reduced at PND 28, we induced 40 min of HI at PND 
28 in mixed litters from Cre-Lox mice. No differences 
in brain injury were seen between WT Lox Trp53+/+ 
(n=8; females n=4, males n=4) and KO Lox Trp53f/+ 
(n=16; females n=8, males n=8) 7 days following HI. No 
differences were observed in loss of MAP-2 (total group 
or separated for sex), volume tissue loss or loss of MBP 
(Figure 5). We also performed neuropathology scoring 
of the different regions and found that brain injury in the 
juvenile brain (PND 28) was observed in the same regions 
(hippocampus, thalamus, striatum and cortex) as in the 
immature (PND 9 or PND 12) brain which agree with 
previous work [38]. However, we found no difference 
between genotypes following HI at PND 28.
DISCUSSION
In summary, we found that heterozygote Trp53 
gene deficiency conferred partial neuroprotection in the 
Figure 3: β-gal expression in the brains of CaMK2α Cre - Rosa26 reporter mice. CaMK2α Cre mice were bred with ROSA26 
reporter mice; brains were collected at postnatal day (PND) 7 A. PND 14 B. PND 19 C. and PND29 D. Β-gal staining is representative of 
cre-recombinase activity, which occurs from PND 19. Scale bar represents 1000 μm.
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posterior part of the brain including the posterior part of 
the hippocampus, cerebral cortex and thalamus in response 
to a moderate insult of 50 min of HI but not following a 
more severe 60 min insult of HI in PND 9 mice. Brain 
injury was not affected in neonatal (PND 12) or juvenile 
(PND 28) mice by a conditional neuron-selective Trp53 
gene deletion.
The moderate neuroprotection seen in the posterior 
part of the brain in neonatal Trp53 het mice contrasts 
with the profound tissue protection seen in adult mice. 
Adult Trp53 het mice develop ~80% smaller brain injury 
compared with WT controls after ischemia [39]. There 
are several possible explanations for the developmental 
difference in vulnerability dependent on p53. It was 
recently discovered that in the adult brain p53 interacts 
with cyclophilin D (CyD) and the complex induces 
opening of the mitochondrial permeability transition 
(MPT) pore leading to necrotic cell death [39]. Hence 
downregulation of p53 or blockage of CyD with 
cyclosporin A reduces ischemic injury in adults [40, 41]. 
However, in the setting of the immature brain the situation 
is different. Ischemic necrosis doesn’t seem to depend on 
CyD or MPT as cyclosporin A or CyD gene deficiency do 
not confer neuroprotection [14, 42]. Instead, RIP kinase-
dependent necrosis is proposed to be critical for this 
mode of cell death [43]. Speculatively, partial p53 gene 
depletion is markedly protective in the adult brain as CyD 
dependent necrosis and apoptosis are both attenuated. In 
the immature brain, Bax-dependent apoptotic cell death 
is reduced in Trp53 het mice reducing vulnerability 
but the degree of protection is limited as necrosis is 
unaffected. It also could explain why p53 genotype did 
not influence brain injury after a severe insult of 60 min 
HI in the neonates, as necrosis becomes the predominant 
mode of cell death even in the immature brain under those 
conditions [7].
Whilst the ideal comparison to access the effect of 
genetic knockdown would be between Trp53 KO and WT 
pups, it is widely reported that traditional Trp53 KO mice 
develop malignancy throughout the body from a young 
age [44]. Also, whilst all our breeding paradigms were 
generating mixed genotype litters, only very few Trp53 
KO (n=6) pups were born. These pups were subjected to 
60 min HI and no difference between genotypes in injury 
was seen (data not shown). We therefore compared Trp53 
het with Trp53 WT, which, in two studies in the adult 
Figure 4: Trp53 in situ hybridization on brains from WT Lox Trp53+/+, KO Lox Trp53f/+ and Trp53 KO. In situ hybridization 
of Trp53 in WT Lox Trp53+/+ A-D. KO Lox Trp53f/+ E-H. and traditional Trp53 KO I, J. at postnatal day (PND) 7 A, E. PND 12 B, F. 6 
weeks of age C, G. and [higher magnification D, H.]. Traditional Trp53 KO I. higher magnification J. shows no Trp53 staining. Scale bars 
represent 500 μm.
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mouse brain have shown that a partial knockdown of p53 
is sufficient to protect the brain following focal ischemia 
[39, 45].
In order to reduce secondary phenotypic influences 
in conventional knock-out mice we also adopted the Cre-
LoxP system to allow for conditional gene deletion in 
predominantly hippocampal and cortical neurons, regions 
that are vulnerable to near term hypoxic-ischemic injury. 
We chose the promoter CaMK2α [35] where the mRNA for 
CaMK2α is expressed in most brain regions at postnatal 
day 4-14 [46]. This significant increase in expression from 
second to third postnatal week is thought to correlate with 
active forebrain synaptogenesis [47]. However, according 
to our assessment of cre-recombinase activity, through 
breeding with a ROSA26 reporter mouse and staining 
for X-gal, CaMK2α cre-recombinase activation was only 
present from PND 19, consistent with Tsien et al., [37]. 
In addition, our in situ hybridization results also showed 
Trp53 expression was apparent until PND 12, which could 
explain the lack of neuroprotection in Cre-LoxP mice at 
PND 12. But it was surprising that HI brain injury was 
unaffected by conditional neuronal deletion of Trp53 
also at PND 28 considering the marked cre-recombinase 
activation and loss of Trp53 gene expression at this age 
and the protective effect of conventional gene deletion in 
adults [39, 45].
This lack of effect suggests that selective gene 
deletion in neurons is insufficient to alter the extent 
of pan-cellular focal lesions produced in this HI model 
in mice at PND 9-60 [38, 48] and indeed, increasing 
evidence implies that p53 impacts glial function in 
development and neurodegeneration [49]. Enhanced 
expression of p53 in astrocytes has been reported 7 days 
following adult cerebral ischemia in rodents [50] and nitric 
oxide-induced cell death in astrocytes is mediated via p53 
[51]. Overexpression of p53 has also been implicated in 
oligodendrocyte cell death in vitro and p53 expression is 
strongly associated with oligodendrocyte destruction in 
lesions of adult patients with multiple sclerosis [52, 53]. 
In addition to an essential role in cell death, p53 is also 
associated with oligodendrocyte precursor cell (OPC) 
development, where the optic nerve in Trp53 knockout 
mice at PND 7 showed an increase in OPC number but a 
decrease in the number of oligodendrocytes [54].
In models of demyelination, genetic knock down 
(Trp53 knockout mice) or pharmacological inhibition 
Figure 5: Brain injury assessment of WT Lox Trp53+/+ and KO Lox Trp53f/+ mice 7 days following 40 min HI at PND 
28. MAP-2 tissue loss A. volume tissue loss B. MBP loss C. and neuropathology score D. were assessed in WT Lox Trp53+/+ (black bars; 
n=8) and KO Lox Trp53f/+ (grey bars; n=16). Mean ± SEM. Cortex (Cx), Hippocampus (Hipp), Striatum (Stri), Thalamus (Thal).
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(PFT-α) of p53 resulted in preservation of myelinated 
fibres and increased oligodendrocyte survival [55]. 
This study also found decreased microglial activation 
and recruitment to the site of injury (corpus callosum) 
[55]. P53 expression in microglia has been shown to 
promote a pro-inflammatory phenotype that is damaging 
to neuronal synapses [56]. Numerous studies have also 
found that reduced expression of p53, such as in Trp53 
knockout mice or following inhibition (PFT-μ), results 
in increased expression of anti-inflammatory genes and 
functions leading to tissue repair and phagocytosis, 
suggesting that in microglia, p53 modulates the 
activation state [33, 55, 57]. These studies indicate 
that the role of p53 in other cell types can significantly 
contribute to the progression of injury, and could explain 
the lack of protection following neuronal knockdown of 
Trp53. Additionally, this could have a greater impact in 
the adult and ageing brain.
Our findings strongly suggest that the CaM2Kα, 
from the T29-1 line, is not the ideal choice for neonatal 
experiments considering Cre, under the promoter of 
CamK2α, is not active till after PND 14. Whilst these 
experiments were being conducted the online cre 
repository was being characterized as a global resource 
[58]. As a consequence, it was recognized that Cre 
inherited from the maternal or paternal line can differ in 
expression, although we did not see this. In addition, it 
is important to recognize that Cre expression can differ 
between litter mates and other organs may be affected, all 
of which are important considerations when choosing a 
Cre line.
The partial neuroprotection we found in Trp53 het 
mice in response to moderate HI (50 min HI) is more 
subtle and limited to the posterior part of the brain in 
response to moderate degrees of HI when compared with 
our previous demonstration that PFT-μ reduces brain 
injury globally after neonatal HI [31]. The degree of 
neuroprotection exerted by PFT-μ was considerably more 
pronounced than by heterozygote Trp53 gene deficiency. 
This discrepancy could be due to that the degree of gene 
deletion was only partial (comparing Trp53 het vs. Trp53 
WT) and that the cerebroprotective effect of PFT-μ is 
complex and not solely explained by its blockage of 
p53 interaction at the outer mitochondrial membrane. 
PFT-μ interacts with HSPs [34] and modulates the 
immuno-inflammatory response [33] which certainly 
could contribute to its neuroprotective efficacy in HI. In 
addition to PFT-μ, PFT-α has been used to inhibit the 
transcriptional activity of p53 which results in decreasing 
p53 DNA binding activity [59, 60]. Treatment with 
PFT-α given prior to [61], 1-6h following [62], or 6–9 
days [63] following adult cerebral ischemia resulted in 
neuroprotection.
In summary, we have found that partial knockdown 
of Trp53 is protective following a moderate hypoxic-
ischemic insult in posterior regions of the immature brain. 
More severe insults and conditional neuronal knockdown 
in the juvenile brain did not show any level of protection. 
Whilst p53 is a key mediator of neuronal cell death, acting 
upstream of Bax-dependent MOMP in the neonatal brain, 
further studies evaluating mediators of p53 activation 
could reveal new therapeutic targets.
MATERIALS AND METHODS
Ethics statement
All animal experimentation conducted in accordance 
with Department of Agriculture (Jordbruksverket, 
Sweden) and approved by the Gothenburg animal ethics 
committee (Application 52-2012).
Animals
Mice were bred in-house, kept in a 12 hour light/
dark cycle, and fed standard laboratory chow diet and 
drinking water, ad libitum (Experimental Biomedicine, 
University of Gothenburg, Sweden). All mice were 
purchased from The Jackson Laboratory.
Traditional Trp53 Knockouts
Trp53 heterozygote (Het; +/-) mice (Stock #002101; 
B6.129S2-Trp53tm1Tyj/J) [44] were bred together or with 
wild types (WT; +/+ [generated from Trp53 het-het cages]) 
to produce mixed genotypes; Trp53 knockout (KO; -/-), 
Trp53 het and Trp53 WT. Trp53 knockout mice tend to 
develop tumors in early life and were therefore not used 
in these studies. Mixed litters (Trp53 het and Trp53 WT) 
were used for HI experiments as previously described in 
adult experiments on ischemia [39].
Cre-LoxP conditional knockouts
Neuronal specific knockdown of Trp53 was 
achieved utilizing Cre-LoxP technology. Briefly, LoxP 
mice containing the (floxed) Trp53 allele (Lox; Cre-/- 
Lox+/+, strain #008462; B6.129P2-Trp53tm1Brn/J) were bred 
with mice expressing Cre recombinase under the promoter 
of calcium/calmodulin-dependent protein kinase II alpha, 
of the T29-1 line (Cre; Cre+/+ Lox-/-, CaMK2α-Cre T29-1, 
Stock# 005359; B6.Cg-Tg(CaMK2α-cre)T29-1Stl/J). First 
generation (Cre+/+ Lox-/- x Cre-/- Lox+/+) breeding resulted 
in heterozygote Cre-Lox mice (Cre+/- Lox+/-). These were 
subsequently bred with Lox mice to produce a second 
generation of mixed genotypes [Het Cre-Lox (Cre+/- Lox+/-), 
Hom Lox (Cre-/- Lox+/+), Het Lox (Cre-/- Lox+/-) and 
neuronal specific KO of Trp53 (KO Lox Trp53f/+; Cre+/- 
Lox+/+). These KO Lox Trp53f/+ were bred with Lox mice 
to generate mixed litters: WT Lox Trp53+/+ (Cre-/- Lox+/+) 
and KO Lox Trp53f/+ (Cre+/- Lox+/+) that were used for HI 
experiments.
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Cre-ROSA26 characterization
Currently the online cre portal (http://www.
creportal.org, http://www.informatics.jax.org/allele/
MGI:2177650) only contains information regarding cre 
recombinase activity at ages Embryonic (E) 10.5, E15.5, 
PND 7 and PND 56. To further characterize CaMK2α-
cre T29-1 cre activity we bred with ROSA26 LacZ 
reporter mice (Rosa26+/+; strain #003474 (B6.129S4-
Gt(ROSA)26Sortm1Sor/J) [58], which generated Cre+/- 
Rosa26+/-. Both male and female Cre mice were used to 
breed with Rosa26 reporter mice to further assess whether 
maternal or paternal cre inheritance was different [58]. 
At PND 7, PND 14, PND 19 and PND 29 brains were 
harvested and frozen at -80°C. Coronal sections were 
cut on a cryostat at 10 μm. β-galactosidase staining was 
done following manufacturer instructions (Cat number: 
K1465-01, Invitrogen, Sweden). Sections were visualized 
on a Zeiss Microscope (Model Axio Imager 2, Zeiss, 
Germany) and captured on an AxioCam MRm Camera 
(Zeiss, Germany) using Zen Software (Zeiss, Germany).
Genotyping
The genotype of WT, Het and KO mice were 
determined by polymerase chain reaction (PCR) of 
genomic DNA extracted from tail clips by RedExtract-N-
AMP Tissue PCR Kit (Sigma-Aldrich, USA). All primers 
were ordered from Eurofins MWG GmbH (Ebersberg, 
Germany). For traditional Trp53 transgenic mice; each 
PCR reaction (20μl) contained 2 μl (<250 ng DNA) 
and was made following KAPA Taq DNA Polymerase 
manufacturer’s instructions (KAPA BioSystems, USA) 
and primer concentrations of 0.08 μM IMR7777, 1μM 
IMR7778, 1.17 μM IMR8306. For Cre-Lox and Rosa26 
genotyping: each PCR reaction (10 μl) contained 1 μl 
(50 – 100 ng) of genomic DNA, 5 μl of REDExtract-
N-Amp PCR Reaction mix and all primers were 
used at a concentration of 1 μM. The PCR products 
were separated on a 1.5% agarose/0.5 x Tris-borate-
ethylenediaminetetraacetic acid gel containing SYBR® 
Safe DNA gel stain (Invitrogen, Life Technologies 
Sweden). Primer details, PCR programs and expected 
results are listed in Table 1.
In situ hybridization
Mouse Trp53 complementary DNA was cloned 
from mouse brain total RNA by reverse transcription–
polymerase chain reaction (Multiscribe; Applied 
Biosystems), as recommended by the manufacturer. 
Second-round amplification was performed with 
REDTaq (Sigma-Aldrich, Dorset, United Kingdom) 
and 0.5 μmol/L forward (5′-GGC-AAC-TAT-GGC-
TTC-CAC-C-3′) and reverse (5′-CTC-CGT-CAT-
GTG-CTG-TGA-C-3′) primers (based on accession 
number NM_001127233) using the following cycling 
parameters: 95°C for 5 minutes, 1 cycle; 95°C for 
30 seconds; 65°C for 30 seconds; 72°C for 1 minute, 
30 cycles; 72°C for 5 minutes. Each complementary 
DNA product was directionally cloned into TOPO II 
plasmid (Life Technologies, Carlsbad, CA), which 
incorporates T7 and SP6 RNA polymerase promoters 
flanking the cloning region defined by the HindIII or 
Xba 1 restriction enzyme site. Plasmids were sequenced, 
linearized, and transcribed with T7 (antisense) or SP6 
(sense) RNA polymerases (Sigma) to yield digoxigenin-
dUTP–labelled riboprobes in accordance with the 
manufacturer’s protocol (Ambion, Life Technologies). 
Transcription was performed for 24 hours at 37°C. 
The template complementary DNA was digested away 
by RNase-free DNase (2 U/μL, 15 minutes), and the 
riboprobes were purified (Megaclear Purification and 
Filtration System; Ambion, UK) and quantified by 
spectrophotometry and electrophoresis.
In situ hybridization procedure
WT Lox Trp53+/+ and KO Lox Trp53f/+ pups were 
killed at PND 7, PND 12 and at 6 weeks of age, perfused 
with 0.9% physiological saline, followed by 5% buffered 
formalin. Brains were then paraffin embedded and 6 μm 
sections were cut at the level of the hippocampus. The in 
situ hybridization procedure was conducted as previously 
described [64], with overnight incubation occurring at 
56°C and the 2× saline-sodium citrate washes occurring 
for 30 minutes at 55°C. Adjacent slides incubated with the 
sense probe and hybridization buffer alone were used as 
negative controls for specificity. Sections were visualized 
on a Leica Microscope (Model DM6000B, Leica 
Microsystems, UK) and captured on a MBF Bioscience 
Camera (Model Cx9000, MBF Bioscience, USA) using 
Stereo Investigator software (v5.65, MBF Bioscience, 
USA).
Induction of hypoxia-ischemia in neonatal and 
juvenile mice
Traditional Trp53 knockout mice at PND 9 and 
Cre-Lox mice at PND 12 and PND 28 were subjected to 
unilateral HI, according to the Rice–Vannucci model as 
previously described [36, 38, 65]. Briefly, the left common 
carotid artery was isolated and ligated. Pups recovered 
for 1 h in the parent cage. The litters were then placed 
in a chamber with a humidified hypoxic gas mixture 
(10% oxygen in nitrogen, 36°C) for PND 9 mice, 50 min 
(moderate hypoxia) or 60 min (severe hypoxia), PND 12 
for 50 min, and PND 28 mice for 40 min. After hypoxic 
exposure, pups were returned to their biological dams until 
the conclusion of the experiment (7d post-HI). Mortality 
rates from the end of HI to +7 days post-HI were low: 
PND 9; 50 min and 60 min = 0; PND 12 for 50 min HI 
= 1/41 and PND 28 40 min HI = 2/28. The genotypes of 
these mice pups was not determined.
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Brain injury assessment
Pups were killed, tail samples were collected for 
genotyping and mice were perfused intracardially with 
0.9% physiological saline followed by 5% buffered 
formaldehyde (Histolab; Histolab AB, Sweden) as 
previously described [14, 66]. Paraffin-embedded tissue 
blocks were serially cut into 7 μm coronal sections on 
Superfrost® plus slides (Thermo Scientific, Sweden) 
with every 50th section stained. Microtubule associated 
protein-2 (MAP-2), a neuronal marker expressed in 
neurons and dendrites, and myelin basic protein (MBP), a 
major constituent of the myelin sheath of oligodendrocytes 
where loss of staining indicated infracted areas and MBP 
associated white matter loss respectively as previously 
described [14, 66]. Images were taken on a Nikon 
Optiphot-2 (Nikon, Japan) using an AVT Dolphin camera 
(Model 1 F145g, Nikon Germany). Positive stained areas 
were measured using the Olympus Micro Image analysis 
software system (V4.0, Olympus Optical, Tokyo, Japan).
Loss of MAP-2 and MBP staining was determined 
by subtracting the MAP-2 or MBP-positive area in the 
ipsilateral (injured) hemisphere from the contralateral 
(non-injured) hemisphere, and values expressed as 
a percentage of tissue loss from the contralateral 
hemisphere. Total volume loss was calculated according 
to the Cavalieri Principle; V = ΣA x P x T, where V = total 
volume, ΣA = sum of the areas, P = the inverse of the 
sections sampling fraction and T = section thickness. MBP 
staining was measured in the subcortical white matter 
region, at one level of the brain (approximately at the level 
of Bregma -2.12 mm) [67].
Table 1: Primers and PCR programs used for genotyping transgenic mice
Gene Sequence 5’ → 3’ Concentration
(μM)
PCR Program Result
P53 IMR7777 WT 
Forward
ACA GCG TGG TGG 
TAC CTT AT
0.08 94°C for 3 min
35 cycles: [94°C 
for 30 sec; 66°C 
for 60 sec; 72°C 
for 90 sec]
72°C for 2 
minutes.
WT: 450 bp
Het: 450bp and 650bp
Mutant: 650 bpIMR8306 Mutant 
Forward
CTA TCA GGA CAT 
AGC GTT GG
1.17
IMR7778 Common TAT ACT CAG AGC 
CGG CCT
1
Cre IMR1084 Transgene GCG GTC TGG CAG 
TAA AAA CTA TC
1 94°C for 5 min
35 cycles: [94°C 
for 30 sec; 52°C 
for 60 sec; 72°C 
for 60 sec]
72°C for 2 min
Transgene: ~100bp
Internal positive 
control: 324 bpIMR1085 Transgene GTG AAA CAG CAT 
TGC TGT CAC TT
1
IMR7338 Internal 
positive 
control 
Forward
CTA GGC CAC AGA 
ATT GAA AGA TCT
1
IMR7339 Internal 
positive 
control 
Reverse
GTA GGT GGA AAT 
TCT AGC ATC ATC C
1
P53 
Lox
IMR8543 Forward GGT TAA ACC CAG 
CTT GAC CA
1 94°C for 5 min
35 cycles: [94°C 
for 30 sec; 56°C 
for 60 sec; 72°C 
for 60 sec]
72°C for 5 min
WT: 270 bp
Het: 270 bp and 390 
bp
Mutant: 390 bp
IMR8544 Reverse GGA GGC AGA GAC 
AGT TGG AG
1
Rosa26 IMR8545 WT 
Reverse
GGA GCG GGA GAA 
ATG GAT ATG
1 94°C for 3 min
35 cycles: [94°C 
for 30 sec; 65°C 
for 60 sec; 72°C 
for 60 sec]
72°C for 2 min
WT: ~650 bp
Het: 340 bp and ~650 
bp
Mutant: 340 bp
IMR8052 Mutant 
Reverse
GCG AAG AGT TTG 
TCC TCA ACC
1
IMR8545 Common AAA GTC GCT CTG 
AGT TGT TAT
1
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Neuropathology was evaluated by an assessor 
blinded to genotype. A modified semi-quantitative scoring 
scale [36, 68] was used to assess injury in the cortex, 
hippocampus, posterior hippocampus, striatum and 
thalamus. Each region was graded for degree of atrophy 
0 to 3 (0 being no atrophy) and cellular infarction and 
necrosis 0 to 3 (0 indicating no injury), resulting to each 
region receiving a score between 0 – 6.
Data analysis
Data are expressed as mean ± SEM. All statistical 
analysis was performed on GraphPad Prism 6 Software 
(GraphPad Software, San Diego, USA), with statistical 
significance set at p< 0.05. Loss of MAP-2, loss of MBP, 
volume tissue loss and neuropathology score were assessed 
by a student’s t-test. Loss of MAP-2, separated for sex 
was assessed by a One-Way ANOVA for each region. If 
significant, a Tukey’s post-hoc analysis was conducted.
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